Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to ...

Retifanlimab-dlwr (Zynyz) has been granted approval from the FDA for treatment of locally recurrent or metastatic squamous ...

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Panelists discuss how simpler treatment regimens with fewer restrictions, such as the new nilotinib formulation without ...

T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

The extended injection time for subcutaneous daratumumab in those with myeloma can serve as an opportunity for oncology nurses to check in with patients.

Cilta-Cel Associated With Higher HRQOL for Lenalidomide-Refractory MM ...

Telisotuzumab vedotin-tllv has earned accelerated approval for use in patients with non-squamous non-small cell lung cancer with high c-Met overexpression. The FDA has granted accelerated approval to ...

Panelists discuss how managing common adverse events associated with tyrosine kinase inhibitors (TKIs) such as nilotinib requires proactive strategies including supportive medications, dose ...